December 15, 2025 4:57pm
Rotation trade continues, with slim pickings in the Dow, S&P as Nasdaq drags deeper
RMi collects, curates, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision
It’s not always time to buy or sell; but it is time to KNOW and why!
Never leave an investor uninformed!
Monday’s RMi Pre-opening Bell: My choice … https://www.regmedinvestors.com/articles/14229
RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): I reiterate WHO is PACKING the Pig that’s Broke … https://www.regmedinvestors.com/articles/13812
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!
I also, follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
Monday: The Dow closed DOWN -41.31 points or -0.09%, the S&P closed DOWN -10.90 points or -0.16 % while the Nasdaq closed DOWN -137.757 points or -0.59%
- Theme of the session: AI debt weighs on market:
Monday’s (my) 40-company covered sector’s advance/decline line opened negative with 12 incliners, 26 decliners and 2 flats ending with a negative close of 15 incliners, 23 decliners and 2 flats
- Certain AI stocks bogged down the broader market during Monday’s session, such as Broadcom (AVGO) and Oracle (ORCL), the 2 names that led a rotation away from AI last week — declining more than 5% and more than 2%, respectively. Others like Microsoft MSFT) also suffered some losses.
Henry’omics: We need to more than consider the macro-economic environment to comprehend the micro re “our” universe of cell and gene therapy (C>) sector
- Economic data reports could set the tone for the market this week. November nonfarm payrolls figures are set for release Tuesday, along with October retail sales figures. These reports were delayed due to the U.S. government shutdown that took place in the fall. <CNBC>
The CBOE Fear (VIX) index closed at 16.56 following Friday’s 15.81 after Thursday’s 14.85, Wednesday’s 15.84, Tuesday’s 16.90 and last Monday’s 16.55
Metrics: Monday …
- The RUT was down -16.94 points or -0.66%,
- The XLV was up +2.10 points or +1.36%,
- The NBI was up +1.46 points or +0.03%;
- The XBI was down -0.15 points or -0.13%
- The IWM was down -1.63 or -0.64%;
- The IBB was up +0.01 points or +0.00%,
- The VIX was up +0.82 points or +5.21% at to 16.56
Q4 – December – 4 positive and 7 negative closes
• November – 1 holiday, 8 positive and 11 negative closes
• October -1 neutral, 11 positive and 12 negative closes
Monday Closing UP (10 of 15)
- Vertex (VRTX +$3.57 after Friday’s +$6.11
- IQVIA Holdings (IQV +$0.81 after Friday’s -$3.72
- Moderna (MRNA +$0.80),
- Capricor Therapeutics (CAPR +$0.64 after Friday’s -$1.16),
- uniQure NV (QURE +$0.60),
- Supernus Therapeutics (SUPN +$0.42 after Friday’s +$0.65),
- BioLife Solutions (BLFS +$0.22 after Friday’s -$0.49),
- Sarepta Therapeutics (SRPT +$0.20),
- Ultragenyx Pharmaceuticals (RARE +$0.18 after Friday’s +$0.03),
- Precigen (PGEN +$0.135 after Friday’s +$0.07),
Flat (2)
- Adverum Biotechnologies ADVM) – acquired
- Brainstorm Cell Therapeutics (BCLI)
Monday’s Closing DOWN (10 of 23):
- Alnylam Pharmaceuticals (ALNY -$6.89 after Friday’s -$15.08),
- Arrowhead Pharma (ARWR -$1.51 after Friday’s -$0.73),
- Ionis Pharmaceuticals (IONS -$1.21 after Friday’s +$1.68
- Lenz Therapeutics (LENZ -$1.19 after Friday’s -$6.36),
- BioNTech (BNTX -$0.77 after Friday’s -$1.19),
- Beam Therapeutics (BEAM -$0.57),
- AxoGen (AXGN -$0.38 after Friday’s +$0.41),
- Wave Life Sciences (WVE -$0.34),
- Mesoblast (MESO -$0.31),
- CRISPR Therapeutics (CRSP -$0.28 after Friday’s -$1.41)
The Bottom Line: More of the … WHYs
- Back on the merry-go-round …
- Most C> sector equities declined Monday after Friday and Thursday’s declines after inclining Wednesday then declining on Tuesday, follow-by positive closes on Monday, then last Friday’s dive, Thursday and Wednesday positive closes following negative closes on the previous Tuesday and Monday.
Maintaining MY opinion (from title): Capricor Therapeutics (CAPR) is overvalued, overbought and headed to a BIG slide … I would also ask if the SEC should investigate the post news run-up and the sudden offering financing pricing … 12/2 pricing, $6.36, offering price of $25.00 to today’s +$0.64 to $26.66?
I believe CAPR got some “friendly” brokers to BUY yet how long will those last???
Not anyone else is on the same page:
- Remaining risks are tied to HOPE-3 and potential priority review dynamics
- Make your own decision to CUT-BACK as regulatory moving pieces will shape the investment narrative
- Investors may wish to stay informed to better track and interpret future shifts in CAPR's soon
- to be evolving story – can you afford to wait and possibly take a hit out-of-the-blue.
Take it a session at a time … the REAL question is … how long will this sentiment and conviction “run” last in the “clean-out-the-exposure” December?
3rd week of December:
- 12/15 – Monday closed negative with 15 positive, 23 negative and 2 flats
2nd December week:
• 12/12 – Friday closed negative with 12 positive, 26 negative and 2 flats
• 12/11 – Thursday closed negative with 18 positive, 19 negative and 3 flats
• 12/10 – Wednesday closed positive with 24 positive, 12 negative and 4 flats
• 12/9 - Tuesday closed negative with 10 positive, 27 negative and 3 flats
• 12/8 - Monday closed positive with 22 positive, 16 negative and 2 flat
Last week,
• 12/5 – Friday closed negative with 13 positive, 26 negative and 1 flat
• 12/4 – Thursday closed positive with 26 positive, 12 negative and 2 flats
• 12/3 – Wednesday closed positive with 35 positive, 4 negative and 1 flat
• 12/2 - Tuesday closed negative with 10 positive, 29 negative and 1 flat
• 12/1 – Monday closed negative with 5 positive, 31 negative and 0 flat
As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!
Welcome to my world of defining the “grey’ in our universe!
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
- “I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!”
Why do I keep repeating, framed in a different para, so investors can make the connection
The top three (3) performing in the session:
- Monday: Vertex (VRTX), IQVIA Holdings (IQV) and Moderna (MRNA)
- Friday: Vertex (VRTX), Regenxbio (RGNX) and Supernus Therapeutics (SUPN)
The worst three (3) in the session:
- Monday: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharma (ARWR) and Ionis Pharmaceuticals (IONS)
- Friday: Alnylam Pharmaceuticals (ALNY), IQVIA Holdings (IQV) and Arrowhead Pharma (ARWR)
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):
The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
